Basit öğe kaydını göster

Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%

dc.contributor.authorSezer, A.
dc.contributor.authorGogishvili, M.
dc.contributor.authorBentsion, D.
dc.contributor.authorKilickap, S.
dc.contributor.authorLowczak, A.
dc.contributor.authorGumus, M.
dc.contributor.authorGladkow, O.
dc.contributor.authorClingan, P.
dc.contributor.authorSriuranpong, V.
dc.contributor.authorRizvi, N.
dc.contributor.authorLee, S.
dc.contributor.authorLi, S.
dc.contributor.authorSnodgrass, P.
dc.contributor.authorNavarro, M.
dc.contributor.authorLowy, I.
dc.contributor.authorRietschel, P.
dc.date.accessioned2020-10-20T10:38:41Z
dc.date.available2020-10-20T10:38:41Z
dc.date.issued2019
dc.identifier.issn1556-0864en_US
dc.identifier.urihttp://hdl.handle.net/11727/4938
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.jtho.2019.08.1345en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectnon-small-cell lung canceren_US
dc.subjectanti-PD-1en_US
dc.subjectcemiplimaben_US
dc.titleCemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%en_US
dc.typeconferenceObjecten_US
dc.relation.journalJOURNAL OF THORACIC ONCOLOGYen_US
dc.identifier.volume14en_US
dc.identifier.issue10en_US
dc.identifier.startpageS638en_US
dc.identifier.endpageS638en_US
dc.identifier.wos000492162203260en_US


Bu öğenin dosyaları:

Thumbnail
Ad:
PIIS1556086419320283.pdf
Boyut:
165.9Kb
Biçim:
PDF
Göster/Aç

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster